Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union

MLA

“Evergreen Theragnostics Opens CCK2-VIEW, a Phase II Small Cell Lung Cancer Clinical Trial, in the European Union.” Plus Company Updates, 21 Oct. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.813141740&authtype=sso&custid=ns315887.

APA

Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union. (2024, October 21). Plus Company Updates.

Chicago

Plus Company Updates. 2024. “Evergreen Theragnostics Opens CCK2-VIEW, a Phase II Small Cell Lung Cancer Clinical Trial, in the European Union,” October 21. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.813141740&authtype=sso&custid=ns315887.